Cimzia certolizumab pegol: Phase III started

UCB began the double-blind, international Phase III C-EARLY trial to compare subcutaneous Cimzia plus methotrexate vs. placebo plus methotrexate for 52 weeks in about 800 treatment-naïve patients with early, moderate to severe RA. Patients who achieve sustained remission with Cimzia at 52 weeks will be randomized to receive reduced doses or withdrawn from Cimzia for another 52 weeks. ...